Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) shares, rose in value, with the stock price up by 1.76% to the previous day’s close as strong demand from buyers drove the stock to $234.56.
Actively observing the price movement in the last trading, the stock closed the session at $230.50, falling within a range of $228.96 and $235.12. The value of beta (5-year monthly) was 0.297. Referring to stock’s 52-week performance, its high was $304.39, and the low was $141.98. On the whole, ALNY has fluctuated by -7.45% over the past month.
With the market capitalization of Alnylam Pharmaceuticals Inc currently standing at about $30.51 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-12.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 2.89B, with a low estimate of 532M and a high estimate of 706.2M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 588.12M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ALNY’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ALNY currently trading nearly -7.19% and -6.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.36, while the 7-day volatility ratio is showing 4.96% which for the 30-day chart, stands at 6.75%. Furthermore, Alnylam Pharmaceuticals Inc (ALNY)’s beta value is 0.24, and its average true range (ATR) is 15.38.
A comparison of Alnylam Pharmaceuticals Inc (ALNY) with its peers suggests the former has fared considerably weaker in the market. ALNY showed an intraday change of 1.76% in last session, and over the past year, it grew by 59.87%%.
Data on historical trading for Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) indicates that the trading volumes over the past 10 days have averaged 1.34 and over the past 3 months, they’ve averaged 903.65K. According to company’s latest data on outstanding shares, there are 129.29 million shares outstanding.
Nearly 4.40% of Alnylam Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 95.67% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.99 million shares as on 2025-03-31, resulting in a short ratio of 3.29. According to the data, the short interest in Alnylam Pharmaceuticals Inc (ALNY) stood at 306.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.49 million. The stock has fallen by -0.32% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALNY stock heading into the next quarter.
